No Data
No Data
Changmao Biotech (00954.HK) obtained 120,000 H shares from Rui Xinsheng, worth approximately HK$492,000
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $120,000 at an average price of HK$0.41 per share on April 24, worth about HK$492,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 11.92 million shares, and the good position ratio increased from 6.42% to 6.49%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? Major shareholders (individuals and companies holding 5% or more of the shares) as required by the Hong Kong Stock Exchange
Changmao Biotech (00954.HK) received 2.196 million H shares from Rui Xinsheng, worth approximately HK$835,600
On April 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 22, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) $2.196 million at an average price of HK$0.3805 per share on April 19, worth about HK$835,600. After increasing its holdings, Rui Xinsheng's latest shareholding was 11.8 million shares, and the good position ratio increased from 5.23% to 6.42%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (those holding 5% or more of the shares
常茂生物:年報 2023
Changmao Biotech (00954.HK) obtained 80,000 H shares from Rui Xinsheng, worth about HK$32,000
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Rui Xinsheng increased its H share holdings of $80,000 by $Changmao Biotech (00954.HK) at an average price of HK$0.4 per share on April 11, worth about HK$32,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 9.48 million shares, and the good position ratio increased from 5.12% to 5.16%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) must disclose their
Changmao Biotech (00954.HK) received 124,000 H shares from Rui Xinsheng, worth approximately HK$49,900
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $124,000 at an average price of HK$0.4026 per share on April 12, worth about HK$49,900. After the increase in holdings, Rui Xinsheng's latest shareholding was 9.640 million shares, and the good position ratio increased from 5.16% to 5.23%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals holding 5% or more of the shares
Changmao Biotech (00954.HK) obtained 60,000 additional H shares worth HK$23,500 from Rui Xinsheng
On April 8, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 8, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $60,000 at an average price of HK$0.3913 per share on April 5, worth about HK$23,500. After increasing its holdings, Rui Xinsheng's latest shareholding was 9.4 million shares, and the good position ratio increased from 5.08% to 5.12%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their
No Data